Jan 14, 2020 Announcements and research updates from the The Women's Alzheimer's Movement - WAM and UCI MIND Initiative to fund sex disparities in #Alzheimers research at University of California, Irvine. Congratulations to Mathew Blurton-Jones, PhD and Sunil Gandhi, PhD from the UCI School of Biological Sciences and Anshu Agrawal, PhD from the UCI School of Medicine, recipients of seed funding grants made possible by WAM Founder Maria Shriver and the Living Legacy Foundation led by VP and Executive Director Alisha Ballard.
Read More
ASK THE DOC! UCI MIND Facebook LIVE Video Series This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. When will we have an effective treatment for Alzheimer's disease? About the Speaker: Joshua Grill, PhD, is an Associate Professor of Psychiatry & Human Behavior and Neurobiology & Behavior at UCI. He serves…
Read More
Contributed by Keith Swayne, UCI MIND Leadership Council Outstanding Philanthropist Keith Swayne, center, with Honorary Chairs and 2019 Legacy award honorees for Ueberroth Family Foundation Ginny Ueberroth, left, and Vicki Booth, right.(Tony Lattimore and Carla Rhea) - Daily Pilot It is humbling to be recognized as Philanthropist of the Year, particularly when I think about the many individuals who are working to make a difference in the world. The OC National Philanthropy Day event brought together Orange County philanthropists and non-profit organizations to celebrate our shared vision of improving our community. This is what drives me. I wish to use…
Read More
Contributed by Joshua Grill, PhD On Thursday, December 5, attendees at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference heard more from Biogen about its recently resurrected drug, aducanumab (see previous Blog). New data were presented that were consistent with what had previously been shared. Biogen claims that a single positive Phase 3 trial of aducanumab and a secondary analysis of data from a second, negative Phase 3 trial suggest a benefit among patients receiving the highest dose for the full duration of the study (18 months). In both cases, high dose aducanumab appeared to slow the rate of disease…
Read More
Contributed by Chelsea Cox, MPH, MSW, Associate Director of Education In a recent study, researchers at the University of Michigan analyzed survey responses from over 1,000 adults age 50 to 64 to learn about their perceived risk for developing dementia and any actions they take to reduce their own risk. The study found that more than half of respondents believed they were not likely to develop dementia, with this outlook being more common in non-Hispanic blacks who are, in fact, at a greater risk of developing dementia than non-Hispanic whites. The vast majority of respondents reported having never discussed risk…
Read More
UCI MIND faculty member, Dr. Ruth Benca, discussed sleep, brain health, and Alzheimer’s disease at the October 2019 #MIHealthSummit in Washington, D.C., hosted by the Milken Institute. The session opens with a conversation with Maxine Waters, U.S. Representative of California, followed by a panel discussion among leading researchers and policymakers on the latest evidence regarding reducing risk for cognitive decline, including nutrition, exercise, sleep, socialization, and stress management. View the plenary session below.
Read More
Contributed by Bryce Mander, PhD A new landmark study from researchers in Boston was published in Science this month. This study linked human brain waves during deep sleep, called “slow waves,” with the pulsating flow of cerebrospinal fluid (CSF) through the brain. Fultz et al., 2019, NPR This study is important because it is the first to directly link sleeping brain waves with a mechanism thought to clear the brain of metabolic waste and toxins, called the “glymphatic system.” Prior studies in rodents indicate that the glymphatic system actively clears Alzheimer’s disease pathology, as well as other toxins and…
Read More
Contributed by David Sultzer, MD, Professor of Psychiatry & Human Behavior This past weekend, China’s regulatory agency conditionally approved sodium oligomannate for the treatment of mild to moderate Alzheimer’s disease. The approval was based on results from a 9-month treatment study of 818 people, and is the first approval globally of an Alzheimer’s drug in 16 years. Oligomannate (GV-971) is a plant-based complex sugar derived from ocean seaweed. It’s thought to adjust the microbiome in the GI tract, thereby tweaking amino acid levels in the body and reducing the toxic effects of brain inflammation that contribute to Alzheimer’s disease. Results from…
Read More
Facebook Live Series - ASK THE DOC: Alzheimer's Research Today! This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) the first Friday of every month from 9:00-9:30 AM PST to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. Episode 10: "Will I get Alzheimer's if I live long enough?" This month, we're joined by Maria Corrada, ScM, ScD, Professor of Neurology…
Read More
Contributed by Joshua Grill, PhD Yesterday morning, Biogen announced the company’s intention to file with the FDA for approval of Aducanumab, a monoclonal antibody that until recently had been in development as a potential disease-modifying therapy for Alzheimer’s disease. The news came as a shock to us, since two large Phase 3 clinical trials of Aducanumab had been halted for futility earlier in 2019. “Futility” is defined as an early indication that a trial is not likely to demonstrate a drug benefit. As a site for one of those trials, we – along with the research participants and the entire…
Read More
Facebook Live Series - ASK THE DOC: Alzheimer's Research Today! This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) the first Friday of every month from 9:00-9:30 AM PST to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. Episode 9: "When should I see a doctor about memory concerns?" This month, we're joined by UCI MIND Senior Neuropsychologist, Malcolm Dick, PhD.…
Read More
Join us for the 30th annual research conference on October 25th at the Irvine Marriott Hotel. Come learn from internationally renowned experts about how far we have come and where we are headed in the battle against Alzheimer's disease. Register now at http://conference.mind.uci.edu
Read More
Contributed by Joshua Grill, PhD Dorene Rentz and her husband, Ray Berggren, at their home in Natick, Mass. Dr. Rentz helped design the cognitive tests used in the A4 Alzheimer’s clinical trial in which her husband is now participating. Photo credit: M. Scott Brauer for the Wall Street Journal Alzheimer’s disease is a public health crisis. UCI MIND investigators regularly speak in public to increase awareness of the magnitude of the problem and the urgency of our work (see Event Calendar). But many of us leave the clinic, laboratory, or office to face this crisis at home as well. In this excellent…
Read More
Learn about the 30th annual conference panel in today's #SpeakerSpotlight: Moderated by UCI MIND Director Joshua Grill, a diverse panel of stakeholders will provide their unique perspective on challenges and successes in Alzheimer's disease research and what they anticipate for the future of the field. Panelists include a research participant, a family caregiver, and clinicians and scientists from University of California, Irvine: Dr. Lisa Gibbs is a Clinical Professor of Family Medicine and Chief of the Division of Geriatric Medicine and Gerontology at UCI School of Medicine. She also serves as Medical Director of the UC Irvine HealthSeniorHealth Center in Orange…
Read More
. . . And there are nearly 10 million new cases each year. Today is World Alzheimer’s Day. It is a day to remember those we have lost, honor those still fighting, and acknowledge those dedicated to finding a cure. To all the patients, families, research participants, study partners, donors, community members, faculty, staff, and students working with UCI MIND to rid the world of Alzheimer’s disease and related dementias, thank you! UCI MIND collaborates with researchers worldwide to solve this health crisis, and you, too, can be a part of the solution right here in Orange County. Join us…
Read More
Contributed by David Sultzer, MD, Professor of Psychiatry & Human Behavior Last week, Acadia Pharmaceuticals announced findings from its trial of pimavanserin for treatment of delusions and hallucinations related to dementia: Participants treated with pimavanserin had better outcomes than those treated with placebo. The study design was different from usual treatment comparisons of drug and placebo. In this trial, all participants with psychosis symptoms along with Alzheimer’s disease or another cognitive disorder were treated with pimavanserin for 12 weeks. Those who showed improvement were then assigned to either continue taking the drug or cross over to placebo treatment. The study…
Read More
What lifestyle factors increase and decrease risk for Alzheimer’s disease? October 25th Research Conference #SpeakerSpotlight: Dr. Rebecca Gottesman is a board-certified Neurologist and Professor of Neurology and Epidemiology at Johns Hopkins University. Her research focuses on the short-term and long-term cognitive effects of heart disease and stroke. She uses a combination of clinical studies in patients and epidemiological studies to evaluate the impact of heart disease on the brain. In the session, “Risk and Prevention Across the Lifespan,” Dr. Gottesman will discuss the link between heart health and brain health and identify lifestyle factors that increase and decrease risk for…
Read More
How can “smart” technology be used to detect cognitive problems? October 25th Research Conference #SpeakerSpotlight: Dr. Rhoda Au is a Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University and has served as an investigator on the Framingham Heart Study since 1990, conducting research related to cognitive aging and dementia. Dr. Au’s research focuses on a how “bigdata” analytics can better inform our understanding of Alzheimer’s disease. In the session, “Detection in the Digital Era,” Dr. Au will discuss how innovative technology can be used to track cognitive performance in older adults. Attendees will learn how digital technologies…
Read More
Join us October 7th for ASK THE DOC! Time: Monday, October 7 @ 6:00-8:00 PM Location: Fullerton Public Library (353 W Commonwealth Ave, Fullerton, CA 92832) RSVP: bit.ly/UCIaskthedoc (link is case-sensitive) or 800.272.3900 UCI MIND's quarterly ASK THE DOC Q&A panel provides a unique opportunity for the community to have their most pressing questions answered by Orange County's experts in brain health, Alzheimer's disease, and dementia.
Read More
Facebook Live Series - ASK THE DOC: Alzheimer's Research Today! This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) the first Friday of every month from 9:00-9:30 AM PST to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. Episode 8: "What have researchers learned from brain donations?" This month, we're joined by Edwin Monuki, MD, PhD. Dr. Monuki is a neuropathologist,…
Read More
How are brain scans improving our understanding of Alzheimer’s disease? October 25th Research Conference #SpeakerSpotlight: Dr. William Jagust is a Professor of Public Health and Neuroscience at UC Berkeley and heads the national Alzheimer’s Disease Neuroimaging Initiative’s (ADNI) Core Laboratory for PET imaging. His laboratory was the first to describe Alzheimer’s-related hippocampal atrophy quantified with MRI and has continued to pioneer approaches using brain imaging to improve understanding of aging and dementia. In the session “Brain Scans and Biomarkers,” Dr. Jagust will describe how brain imaging has helped advance the field and discuss the strengths and challenges of brain scan…
Read More
How are donated human brains used to study Alzheimer’s disease? October 25th Research Conference #SpeakerSpotlight: Dr. Julie Schneider is a board-certified Geriatric Neurologist and Neuropathologist, Professor of Pathology and Neurological Sciences at Rush University, and Associate Director of the Rush Alzheimer’s Disease Center. Dr. Schneider’s research focuses on linking pathology with risk factors and brain imaging to improve understanding of cognitive aging and dementia. Brain donation has been an invaluable resource for researchers to better understand the causes of and treatment options for Alzheimer's disease and related dementias. In the session, “Gifted Brains Yield Priceless Gains,” Dr. Schneider will discuss…
Read More
In this issue of MIND Matters: UCI MIND Scientists Discover Exercise Can Reprogram Genes Welcome, New Faculty & Staff New FDA Black Box Warning for Insomnia Medications Announcing the 10th Annual UCI MIND Gala Honorees... And more! Download Newsletter > Upcoming Events: Facebook LIVE Q&A Series: "What have researchers learned from brain donations?" Friday, September 6 | 9:00-9:30 am | UCI MIND Facebook Page Follow @UCIrvineMIND to receive notifications when we go LIVE Live online Q&A with Edwin Monuki, MD, PhD, Professor and Warren L. Bostick Chair of Pathology in the UCI School of Medicine. Attend the video live on our Facebook page or view archived…
Read More
Contributed by Bryce Mander, PhD Getty Images Our colleagues at UCSF recently published findings in the journal Alzheimer’s and Dementia examining how tau pathology in different brain diseases – Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degeneration – impacts brain cells that are in charge of keeping us awake. This study reported several important findings: In all three diseases, there was a reduction in brain cells that help promote cortical arousal. In all three diseases, tau pathology was quite substantial in several of the wake-promoting cells in the brainstem region. Tau pathology in the brainstem in Alzheimer’s disease was associated with…
Read More
Contributed by Joshua D. Grill, PhD A recent article in the New York Times highlights an important set of conundrums regarding amyloid imaging for Alzheimer’s disease. Amyloid imaging can detect with relative certainty whether beta amyloid plaques, which are a pathological hallmark of Alzheimer’s disease, are accumulating in a person’s brain. Conundrum #1: Amyloid scans are not covered by insurance for people with cognitive problems. Research led by our friend Dr. Gil Rabinovici at UCSF has demonstrated that amyloid imaging can and does yield important guidance to clinical care. It can change diagnoses and instruct prescribing decisions (more on this >).…
Read More
Facebook Live Series - ASK THE DOC: Alzheimer's Research Today! This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) the first Friday of every month from 9:00-9:30 AM PST to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. Episode 7: "Can brain scans be used to diagnose Alzheimer's?" This month, we're joined by Craig Stark, PhD. Dr. Stark earned a doctorate…
Read More
iStock Recent stories, including one this week by Washington Post, have highlighted the possible impact of anticholinergic medications on dementia. Some studies note that these medications may have negative side effects that mimic dementia in older adults. Others show a possible increase in dementia risk when taking strong anticholinergics long-term. However, more research is needed to understand this potential link. It's important to speak with your doctor about all your medications regularly, discussing potential benefits, risks, and interactions, to help manage your health over time. To learn more about medications and Alzheimer's disease, view UCI MIND's recent Facebook LIVE episode with…
Read More
Join national experts for the 30th Annual SoCal Alzheimer’s Disease Research Conference! Friday, October 25th Irvine Marriott Hotel How close are we to solving Alzheimer’s disease? What have we learned so far? Where do we go from here? For 30 years, the Annual SoCal Alzheimer’s Disease Research Conference has delivered the latest knowledge in dementia research and care to the Orange County community. In its Pearl Anniversary, join national experts as they explore what we have discovered and charge forward with hope for solutions! Prices will increase after September 1, 2019
Read More
UCI MIND faculty member, Craig Stark, PhD was recently quoted in Science Magazine discussing the critical role scientists play in helping improve society. The article focuses on a push to better understand the science behind addiction, and how scientists are spreading evidence-based treatment knowledge through regional and national seminars. By regularly hosting seminars to gather scientific and legal experts, researchers can better inform the criminal justice system on how to improve substance abuse recovery rates in the incarcerated population. Dr. Stark, a neurobiologist who specializes in brain imaging at UCI, has presented at dozens of these legal seminars, speaking on…
Read More
Stewart Cohen/Getty Images NPR recently spoke on All Things Considered about the EXERT Study, a nationwide clinical trial of exercise led by Carl Cotman, PhD, UCI MIND's Founding Director, and Laura Baker, PhD, Associate Director of the ADRC at Wake Forest School of Medicine. The study involves an 18-month exercise program at the local YMCA for 65-89 year-olds with Mild Cognitive Impairment. Throughout the program, researchers look at participants' cognition, blood flow, atrophy (cell loss), and harmful protein accumulation in the brain. Researchers hope to learn about the clinical effect of exercise, as well as the scientific basis for their…
Read More
Days 3-4 at #AAIC19 included more impressive poster presentations from UCI MIND researchers AND prestigious poster awards received by TWO postdoctoral trainees 👏 Congrats to Drs. Lindsay Hohsfield (Kim Green lab) & Davis Woodworth (Ahmad Sajjadi lab)!Postdoctoral trainee in Dr. Kim Green's lab, Dr. Lindsay Hohsfield, won the Basic & Translational Science Poster Competition at #AAIC19 for her innovative research on the association between microglia and tau pathology in Alzheimer's disease.Postdoctoral trainee with Dr. Ahmad Sajjadi, Dr. Davis Woodworth, won the Diagnosis & Prognosis Poster Competition at #AAIC19 for his innovative research into the utility of MRI detection of atrophy…
Read More
Day 2 of #AAIC19 included lectures on sleep and Alzheimer's disease from Drs. Ruth Benca and Bryce Mander, opportunities for collaboration, and rich discussion over poster presentations from numerous UCI MIND faculty and trainees.Dr. Ruth Benca, UCI Professor & Chair of Psychiatry & Human Behavior, was invited to deliver a plenary lecture among the world's experts in Alzheimer's disease research. #AAIC19Dr. Ruth Benca presented a plenary lecture on sleep and Alzheimer's disease to over 5,000 international investigators at #AAIC19ASK! Open Q&A session with Dr. Ruth Benca after her plenary lecture #AAIC19Dr. Bryce Mander presented on using local slow-wave measured during…
Read More
This week, many UCI MIND researchers are sharing their work and collaborating with researchers across the globe at the Alzheimer's Association International Conference in LA! Check out some photos from Day 1 and stay tuned for updates.#AAIC2019 in LA!Davis Woodworth, a postdoctoral trainee working with Dr. Ahmad Sajjadi presented a poster on using MRI to detect atrophy in hippocampal sclerosis. #AAIC2019UCI MIND project scientist and epidemiologist, Christian Salazar, presented a poster on racial and ethnic differences in willingness to be contacted about research studies. #AAIC2019Dr. Claudia Kawas was asked to present and participate on an esteemed panel discussion of limbic-predominant…
Read More
Facebook Live Series - ASK THE DOC: Alzheimer's Research Today! This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) the first Friday of every month from 9:00-9:30 AM PST to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. Episode 6: "What medications can I take to prevent or treat Alzheimer's?" This month, we're joined by Steven Tam, MD. Dr. Tam is…
Read More
The Global Council on Brain Health (GCBH), in partnership with AARP, recently released an extensive report reviewing the current evidence on brain health supplements. AARP formed the GCBH by bringing together an independent group of scientists, physicians, researchers, and other experts. Click here to learn more about these specialists. The GCBH found that there was a lack of evidence for effectiveness, concerns about false claims in marketing, and uncertainty of the possible risks of brain health supplements, since they are not required to be reviewed for purity, safety, and efficacy. The GCBH concluded that no endorsement could be made for…
Read More
Contributed by Joshua Grill, PhD The field of Alzheimer’s disease drug development received more troubling news yesterday, when the leaders of the GENERATION program halted their prevention clinical trials of a drug aiming to prevent the formation of the beta amyloid protein in people at risk to get Alzheimer’s disease. The GENERATION program is led by investigators at Banner Alzheimer’s Institute and is an important study in people at increased genetic risk to someday develop Alzheimer’s disease, based on the apolipoprotein E (APOE) gene. The trials were stopped because preliminary results indicated that the drug under study, CNP520 (being developed…
Read More
